Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 12 | 2025 | 836 | 1.860 |
Why?
|
| Fever | 3 | 2021 | 122 | 1.410 |
Why?
|
| Candidiasis | 2 | 2023 | 39 | 1.270 |
Why?
|
| Drug Utilization | 2 | 2018 | 64 | 1.020 |
Why?
|
| Antimicrobial Stewardship | 4 | 2021 | 24 | 0.990 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2020 | 83 | 0.860 |
Why?
|
| Febrile Neutropenia | 2 | 2021 | 16 | 0.820 |
Why?
|
| Pharmacy | 1 | 2023 | 9 | 0.800 |
Why?
|
| Organ Transplantation | 3 | 2023 | 295 | 0.780 |
Why?
|
| Staphylococcal Infections | 2 | 2023 | 286 | 0.750 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 85 | 0.740 |
Why?
|
| Enterovirus | 1 | 2022 | 16 | 0.720 |
Why?
|
| Meningitis, Aseptic | 1 | 2022 | 7 | 0.720 |
Why?
|
| Enterovirus Infections | 1 | 2022 | 25 | 0.710 |
Why?
|
| Bacteremia | 3 | 2020 | 108 | 0.710 |
Why?
|
| Meningitis | 1 | 2022 | 22 | 0.710 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2022 | 49 | 0.690 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 184 | 0.680 |
Why?
|
| Respiratory Tract Infections | 3 | 2018 | 110 | 0.650 |
Why?
|
| Neutropenia | 2 | 2020 | 209 | 0.640 |
Why?
|
| Stem Cell Transplantation | 1 | 2021 | 192 | 0.630 |
Why?
|
| Hypersensitivity | 1 | 2020 | 162 | 0.580 |
Why?
|
| Drug Packaging | 1 | 2018 | 7 | 0.570 |
Why?
|
| Neutrophils | 1 | 2020 | 324 | 0.570 |
Why?
|
| Medication Errors | 1 | 2019 | 36 | 0.570 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 73 | 0.560 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 401 | 0.540 |
Why?
|
| Guideline Adherence | 2 | 2017 | 236 | 0.530 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2020 | 939 | 0.490 |
Why?
|
| Candida | 1 | 2016 | 20 | 0.490 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 5 | 0.480 |
Why?
|
| Retrospective Studies | 14 | 2025 | 10166 | 0.480 |
Why?
|
| Blood Culture | 1 | 2016 | 13 | 0.480 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 36 | 0.470 |
Why?
|
| Pneumococcal Vaccines | 1 | 2015 | 33 | 0.440 |
Why?
|
| Oseltamivir | 1 | 2015 | 9 | 0.440 |
Why?
|
| Electronic Health Records | 1 | 2019 | 372 | 0.440 |
Why?
|
| Streptococcus pneumoniae | 1 | 2015 | 51 | 0.440 |
Why?
|
| Pneumococcal Infections | 1 | 2015 | 46 | 0.430 |
Why?
|
| Pneumonia | 1 | 2016 | 193 | 0.430 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 74 | 0.420 |
Why?
|
| Social Media | 1 | 2016 | 111 | 0.420 |
Why?
|
| Viruses | 1 | 2015 | 64 | 0.420 |
Why?
|
| Virus Diseases | 1 | 2015 | 83 | 0.420 |
Why?
|
| Education, Medical | 1 | 2016 | 228 | 0.400 |
Why?
|
| Antiviral Agents | 2 | 2021 | 364 | 0.400 |
Why?
|
| Humans | 34 | 2025 | 93522 | 0.390 |
Why?
|
| Escherichia coli | 1 | 2016 | 563 | 0.390 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 557 | 0.360 |
Why?
|
| Neoplasms | 3 | 2024 | 3169 | 0.360 |
Why?
|
| Leukocyte Count | 2 | 2023 | 210 | 0.350 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 660 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2544 | 0.340 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 338 | 0.340 |
Why?
|
| Surgical Wound Infection | 3 | 2020 | 237 | 0.330 |
Why?
|
| Vancomycin | 2 | 2023 | 75 | 0.310 |
Why?
|
| HIV Infections | 1 | 2019 | 961 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1054 | 0.290 |
Why?
|
| Child, Preschool | 3 | 2021 | 3829 | 0.270 |
Why?
|
| Immunocompromised Host | 3 | 2024 | 137 | 0.270 |
Why?
|
| Aged | 16 | 2025 | 20439 | 0.260 |
Why?
|
| Transplant Recipients | 4 | 2023 | 157 | 0.260 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2017 | 66 | 0.250 |
Why?
|
| Geriatric Assessment | 2 | 2019 | 188 | 0.240 |
Why?
|
| Antifungal Agents | 2 | 2017 | 122 | 0.240 |
Why?
|
| Female | 18 | 2025 | 48708 | 0.240 |
Why?
|
| Disease Management | 2 | 2019 | 358 | 0.240 |
Why?
|
| Chicago | 2 | 2021 | 1464 | 0.230 |
Why?
|
| Child | 4 | 2021 | 7355 | 0.220 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 333 | 0.220 |
Why?
|
| Laryngeal Neoplasms | 2 | 2016 | 89 | 0.220 |
Why?
|
| Adolescent | 5 | 2021 | 9607 | 0.210 |
Why?
|
| Pneumocystis carinii | 1 | 2023 | 3 | 0.210 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2023 | 16 | 0.210 |
Why?
|
| Transplantation, Homologous | 3 | 2021 | 1014 | 0.200 |
Why?
|
| Hospitalization | 2 | 2020 | 937 | 0.200 |
Why?
|
| Adult | 9 | 2023 | 27921 | 0.180 |
Why?
|
| Multiplex Polymerase Chain Reaction | 3 | 2018 | 38 | 0.170 |
Why?
|
| Male | 15 | 2025 | 44564 | 0.170 |
Why?
|
| Intensive Care Units | 1 | 2025 | 454 | 0.170 |
Why?
|
| Lactams | 1 | 2020 | 13 | 0.170 |
Why?
|
| beta-Lactams | 1 | 2020 | 15 | 0.160 |
Why?
|
| Syndrome | 1 | 2021 | 437 | 0.160 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2023 | 277 | 0.160 |
Why?
|
| Invasive Fungal Infections | 1 | 2020 | 10 | 0.160 |
Why?
|
| Medical Overuse | 1 | 2020 | 30 | 0.160 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 204 | 0.150 |
Why?
|
| Respiratory System | 1 | 2020 | 117 | 0.150 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2020 | 117 | 0.150 |
Why?
|
| Patient Transfer | 1 | 2020 | 108 | 0.150 |
Why?
|
| Middle Aged | 13 | 2025 | 27580 | 0.150 |
Why?
|
| Bordetella Infections | 1 | 2018 | 5 | 0.150 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 133 | 0.140 |
Why?
|
| Pharmacists | 1 | 2019 | 36 | 0.140 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2018 | 9 | 0.140 |
Why?
|
| Risk Factors | 5 | 2024 | 5901 | 0.140 |
Why?
|
| Glucocorticoids | 2 | 2023 | 362 | 0.140 |
Why?
|
| Osmolar Concentration | 1 | 2018 | 168 | 0.140 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 12 | 0.140 |
Why?
|
| Medical Audit | 1 | 2018 | 41 | 0.140 |
Why?
|
| Recurrence | 1 | 2021 | 1191 | 0.140 |
Why?
|
| Levofloxacin | 1 | 2018 | 9 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2025 | 3056 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1723 | 0.130 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 157 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 129 | 0.130 |
Why?
|
| Drug Compounding | 1 | 2018 | 87 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2019 | 406 | 0.130 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 116 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 122 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2019 | 298 | 0.130 |
Why?
|
| Drug Resistance, Microbial | 1 | 2016 | 62 | 0.120 |
Why?
|
| Triazoles | 1 | 2017 | 110 | 0.120 |
Why?
|
| Itraconazole | 1 | 2016 | 12 | 0.120 |
Why?
|
| Empirical Research | 1 | 2016 | 20 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3832 | 0.120 |
Why?
|
| Histocytochemistry | 1 | 2016 | 125 | 0.120 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 25 | 0.120 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 38 | 0.120 |
Why?
|
| DNA, Fungal | 1 | 2016 | 60 | 0.120 |
Why?
|
| RNA, Ribosomal | 1 | 2016 | 65 | 0.120 |
Why?
|
| Autopsy | 1 | 2016 | 126 | 0.120 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 9 | 0.120 |
Why?
|
| Prognosis | 2 | 2021 | 3912 | 0.120 |
Why?
|
| Quality of Health Care | 1 | 2019 | 382 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2016 | 295 | 0.120 |
Why?
|
| Inpatients | 1 | 2019 | 345 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 225 | 0.110 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2479 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 65 | 0.110 |
Why?
|
| Fungi | 1 | 2015 | 67 | 0.110 |
Why?
|
| Laryngectomy | 1 | 2015 | 26 | 0.110 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2015 | 37 | 0.110 |
Why?
|
| Immunization, Secondary | 1 | 2015 | 37 | 0.110 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 87 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2015 | 38 | 0.110 |
Why?
|
| Infant | 1 | 2021 | 3220 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 1001 | 0.110 |
Why?
|
| Cystectomy | 1 | 2015 | 113 | 0.110 |
Why?
|
| Incidence | 2 | 2016 | 1702 | 0.110 |
Why?
|
| Advisory Committees | 1 | 2015 | 90 | 0.110 |
Why?
|
| Early Diagnosis | 1 | 2015 | 135 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2017 | 375 | 0.100 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 383 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 893 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 378 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 826 | 0.090 |
Why?
|
| United States | 3 | 2021 | 7622 | 0.080 |
Why?
|
| Time Factors | 2 | 2020 | 5412 | 0.080 |
Why?
|
| Lung | 1 | 2016 | 1366 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2802 | 0.070 |
Why?
|
| Betacoronavirus | 2 | 2020 | 283 | 0.060 |
Why?
|
| Opportunistic Infections | 1 | 2024 | 57 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2015 | 2563 | 0.050 |
Why?
|
| Pandemics | 2 | 2020 | 873 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 7063 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1917 | 0.050 |
Why?
|
| Europe | 1 | 2023 | 337 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2025 | 482 | 0.050 |
Why?
|
| Critical Illness | 1 | 2025 | 343 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 30 | 0.040 |
Why?
|
| Alanine | 1 | 2021 | 83 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 18 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2024 | 404 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 78 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 119 | 0.040 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 23 | 0.040 |
Why?
|
| Coinfection | 1 | 2020 | 67 | 0.040 |
Why?
|
| Skilled Nursing Facilities | 1 | 2020 | 49 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 150 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 63 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 70 | 0.040 |
Why?
|
| Bordetella bronchiseptica | 1 | 2018 | 6 | 0.040 |
Why?
|
| Bordetella pertussis | 1 | 2018 | 15 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2018 | 113 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 212 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 359 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 887 | 0.030 |
Why?
|
| Dementia | 1 | 2020 | 214 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 353 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 232 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2021 | 541 | 0.030 |
Why?
|
| Palliative Care | 1 | 2019 | 269 | 0.030 |
Why?
|
| Serum | 1 | 2017 | 25 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2017 | 91 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 291 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1914 | 0.030 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 18 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2016 | 36 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1321 | 0.030 |
Why?
|
| Histoplasmosis | 1 | 2016 | 28 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 9103 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 690 | 0.030 |
Why?
|
| Tablets | 1 | 2017 | 127 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 6930 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2017 | 494 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1524 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 365 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1906 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 990 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 2017 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 624 | 0.020 |
Why?
|